These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9875449)

  • 21. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
    Pan XS; Yague G; Fisher LM
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
    Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
    J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotics susceptibility of quinolones against Salmonella spp. strains isolated and molecularly sequenced for gyrA gene.
    Macías-Farrera GP; de Oca Jiménez RM; Varela-Guerrero J; Tenorio-Borroto E; Rivera-Ramírez F; Monroy-Salazar HG; Yong-Angel G
    Microb Pathog; 2018 Jan; 114():286-290. PubMed ID: 29208542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conjugation between quinolone-susceptible bacteria can generate mutations in the quinolone resistance-determining region, inducing quinolone resistance.
    Pitondo-Silva A; Martins VV; Silva CF; Stehling EG
    Int J Antimicrob Agents; 2015 Feb; 45(2):119-23. PubMed ID: 25262036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant Staphylococcus aureus isolates from Japan and China.
    Tanaka M; Zhang YX; Ishida H; Akasaka T; Sato K; Hayakawa I
    J Med Microbiol; 1995 Mar; 42(3):214-9. PubMed ID: 7884804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
    Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
    Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
    Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV.
    Deguchi T; Yasuda M; Nakano M; Kanematsu E; Ozeki S; Ishihara S; Saito I; Kawada Y
    J Antimicrob Chemother; 1997 Feb; 39(2):247-9. PubMed ID: 9069547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium.
    Gensberg K; Jin YF; Piddock LJ
    FEMS Microbiol Lett; 1995 Oct; 132(1-2):57-60. PubMed ID: 7590165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp.
    Maurin M; Abergel C; Raoult D
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2098-105. PubMed ID: 11408229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
    Tani M; Maebashi K; Araake M; Watabe H
    Jpn J Antibiot; 2002 Dec; 55(6):882-5. PubMed ID: 12621742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High prevalence of OXA-143 and alteration of outer membrane proteins in carbapenem-resistant Acinetobacter spp. isolates in Brazil.
    Mostachio AK; Levin AS; Rizek C; Rossi F; Zerbini J; Costa SF
    Int J Antimicrob Agents; 2012 May; 39(5):396-401. PubMed ID: 22455794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of DNA gyrase and topoisomerase IV mutations in fluoroquinolone resistance of Capnocytophaga spp. clinical isolates and laboratory mutants.
    Ehrmann E; Jolivet-Gougeon A; Bonnaure-Mallet M; Fosse T
    J Antimicrob Chemother; 2017 Aug; 72(8):2208-2212. PubMed ID: 28453633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
    Yang J; Luo Y; Cui S; Wang W; Han L
    Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
    Oh H; El Amin N; Davies T; Appelbaum PC; Edlund C
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1977-81. PubMed ID: 11408211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates.
    Vila J; Ribera A; Marco F; Ruiz J; Mensa J; Chaves J; Hernandez G; Jimenez De Anta MT
    J Antimicrob Chemother; 2002 Mar; 49(3):471-7. PubMed ID: 11864947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.
    Zhao X; Xu C; Domagala J; Drlica K
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13991-6. PubMed ID: 9391140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on resistance level.
    Reinhardt AK; Kempf I; Kobisch M; Gautier-Bouchardon AV
    J Antimicrob Chemother; 2002 Oct; 50(4):589-92. PubMed ID: 12356806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.